Provectus Pharmaceuticals Inc. Announces H. Lee Moffitt Cancer Center & Research Institute Initiates Phase 1 Study of PV-10 to Elucidate Bystander Effect
Published: Jan 08, 2013
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional ("IL") PV-10 injection of melanoma tumors. Amod Sarnaik, M.D. member of the Experimental Therapeutics Program at Moffitt and faculty member at the University of South Florida, is the principal investigator for the study, which is expected to enroll up to 15 subjects. Sarnaik said, "We look forward to verifying the promising pre-clinical data from our ongoing work in this translational study. These results should help elucidate the immunologic basis of the ‘bystander effect’ noted in previous clinical studies of PV-10 and help optimize PV-10 treatment, particularly in combination with other therapies. As Moffitt pursues its mission of contributing to the prevention and cure of cancer, we are pleased to spearhead this important clinical work."